LABORATORY NEWS
-
Labcorp Launches FDA-Approved Companion Diagnostic To Identify Patients With Ovarian Cancer Eligible For KEYTRUDA®
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA®.i
- HistoIndex Extends Access To Its MASH Diagnostic Offering Through New Partnerships In Texas And California
- SYNERGEN Health Introduces IGNITE End-To-End Diagnostic Revenue Cycle Solution To Transform Laboratory RCM Performance
- Space-Efficient Cryogenic Sample Storage
- Astrin Biosciences Earns CAP Accreditation For World's First Deep Proteomics Blood Test For Breast Cancer Detection
ARCHIVED NEWSLETTER
- 04.21.26 -- Proteomics Tools: A Resurrection
- 04.07.26 -- Navigating GMP Biosafety Challenges In ATMP Manufacturing
- 02.24.26 -- Rethinking Disease Modification Through Targeted Immunotherapy
- 02.10.26 -- Why Use Total Organic Carbon Analysis For Cleaning Validation?
- 01.20.26 -- Rats Behind The Wheel: The Right Preclinical Way To Investigate Drug Effects On Driving?